Metanálise mostra que há baixo risco de uma segunda reação alérgica a vacinas de mRNA contra SARS-CoV-2 em pacientes que apresentaram tal reação na primeira dose.
22 Fev, 2022 | 15:40h
Comentário no Twitter
Systematic review and meta-analysis of 22 studies and 1366 patients found that there was a low risk of repeat allergic reaction to a second #COVID19 mRNA vaccine dose in people who had immediate allergic reaction with the first dose. https://t.co/NQSXBJwa6r
— JAMA Internal Medicine (@JAMAInternalMed) February 21, 2022